FDA Approves Abemaciclib (Verzenio) for Advanced HR+ Breast Cancer

The new drug is similar to two other cyclin-dependent kinase (CDK) 4/6 inhibitors, but it also has some distinguishing qualities.
FDA Approvals

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.